TP53 and non-small cell lung carcinoma: Concomitant defects in multiple cell cycle checkpoints, including p53 and Rb pathways, exacerbate adverse outcomes, with deregulated cell cycle genes serving as independent prognostic markers and predictors of chemotherapy response in NSCLC [61].